Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201085 | 0.88 | HRH4 (0.41) | HRH4ABCB1MEN1KMT2AGAA | |
| SCHEMBL13385715 | 0.86 | HRH4 (0.34) | HRH4ABCB1 | |
| SCHEMBL13401594 | 0.84 | HTT (0.35) | ABCB1MEN1KMT2AGAAMAPT | |
| SCHEMBL13020891 | 0.80 | MEN1 (0.31) | MEN1KMT2AGAAMAPTHTT | |
| SCHEMBL14012235 | 0.78 | HRH4 (0.45) | HRH4MEN1KMT2ADRD3POLB | |
| SCHEMBL13897391 | 0.78 | ALDH1A1 (0.32) | ABCB1MEN1KMT2AGAAMAPT | |
| SCHEMBL13933657 | 0.78 | ABCC1 (0.34) | ABCB1MEN1KMT2AGAAMAPT | |
| SCHEMBL13401447 | 0.78 | SYK (0.39) | HRH4MEN1KMT2APDGFRBPDGFRA | |
| SCHEMBL13020887 | 0.77 | HRH4 (0.43) | HRH4ABCB1MEN1KMT2AGAA | |
| SCHEMBL12201081 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034959-B2 | Methods of treating cancer with an antibody-drug conjugate | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034959-B2 | Methods of treating cancer with an antibody-drug conjugate | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7977465-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977465-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-RE41252-E1 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-RE41252-E1 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | MEDAREX, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | MEDAREX, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | MEDAREX, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7507420-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507420-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7498302-B2 | Disulfide prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498302-B2 | Disulfide prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | PDIA5, CD38, DUT | HRH4 1037/4885ABCB1 433/4885MEN1 619/4885 |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | VIP, PIN1, PDF | HRH4 2126/4885ABCB1 757/4885MEN1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.